FDA clearance in 2003 “as an adjunctive therapy for reducing the level of pain and symptoms associated with osteoarthritis of the knee and for overall improvement of the knee as assessed by the physician’s global evaluation (see clinical studies).
First and only non-drug, non-invasive option for relieving pain and symptoms associated with osteoarthritis of the knee.
More than 4,000 physicians have prescribed this unique treatment for more than 80,000 patients.